Introduction We have previously shown that a subpopulation of naturally occurring human IgGs has therapeutic potential for the amyloid-associated disorders. These molecules cross-react with conformational epitopes on amyloidogenic assemblies, including amyloid beta (Aβ) protein fibrils that are a pathological hallmark of Alzheimer's disease. Materials and Methods Using our europium-linked immunosorbant assay, we established that ~95% of 260 screened donor plasma samples had amyloid fibril-reactive IgGs and Aβ conformer-reactive IgGs with minimal binding to Aβ monomers. Anti-amyloidogenic reactivity was diverse and attributed to Aβ targeting multiple fibril-related binding sites and/or variations in multidentate binding. Results and Discussion There was no correlation between anti-fibril and anti-oligomer reactivity and donor age (19 to 60 years old) or gender. These findings demonstrate the inherent but diverse anti-amyloidogenic activity of natural IgGs contained in normal plasma. Conclusion Our studies provide support for investigating the clinical significance and physiological function of this novel class of antibodies. © Springer Science+Business Media, LLC 2010.
CITATION STYLE
O’Nuallain, B., Williams, A. D., McWilliams-Koeppen, H. P., Acero, L., Weber, A., Ehrlich, H., … Solomon, A. (2010). Anti-amyloidogenic activity of IgGs contained in normal plasma. Journal of Clinical Immunology, 30(SUPPL. 1). https://doi.org/10.1007/s10875-010-9413-6
Mendeley helps you to discover research relevant for your work.